|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee S, Hwang N, Seok BG, Lee S, Lee SJ and
Chung SW: Autophagy mediates an amplification loop during
ferroptosis. Cell Death Dis. 14:4642023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kinowaki Y, Taguchi T, Onishi I, Kirimura
S, Kitagawa M and Yamamoto K: Overview of ferroptosis and synthetic
lethality strategies. Int J Mol Sci. 22:92712021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alborzinia H, Chen Z, Yildiz U, Freitas
FP, Vogel FCE, Varga JP, Batani J, Bartenhagen C, Schmitz W, Büchel
G, et al: LRP8-mediated selenocysteine uptake is a targetable
vulnerability in MYCN-amplified neuroblastoma. EMBO Mol Med.
15:e180142023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Floros KV, Cai J, Jacob S, Kurupi R,
Fairchild CK, Shende M, Coon CM, Powell KM, Belvin BR, Hu B, et al:
MYCN-amplified neuroblastoma is addicted to iron and vulnerable to
inhibition of the system Xc-/glutathione axis. Cancer Res.
81:1896–7908. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu Y, Yang Q, Su Y, Ji Y, Li G, Yang X, Xu
L, Lu Z, Dong J, Wu Y, et al: MYCN mediates TFRC-dependent
ferroptosis and reveals vulnerabilities in neuroblastoma. Cell
Death Dis. 12:5112021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lei G, Zhuang L and Gan B: Targeting
ferroptosis as a vulnerability in cancer. Nat Rev Cancer.
22:381–396. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Labrie M, Brugge JS, Mills GB and
Zervantonakis IK: Therapy resistance: Opportunities created by
adaptive responses to targeted therapies in cancer. Nat Rev Cancer.
22:323–339. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai Y, Lv L, Lu T, Ding M, Yu Z, Chen X,
Zhou X and Wang X: α-KG inhibits tumor growth of diffuse large
B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis. Cell
Death Discov. 9:1822023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu X and Li S: Ferroptosis, necroptosis,
and pyroptosis in gastrointestinal cancers: The chief culprits of
tumor progression and drug resistance. Adv Sci (Weinh).
10:e23008242023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu L, Jin H, Dong M, Tian J, Li H, Liu Q,
Chen Y and Zou Z: Identification of ferroptosis-related signature
with potential implications in prognosis and immunotherapy of renal
cell carcinoma. Apoptosis. 27:946–960. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang W, Jiang B, Liu Y, Xu L and Wan M:
Bufotalin induces ferroptosis in non-small cell lung cancer cells
by facilitating the ubiquitination and degradation of GPX4. Free
Radic Biol Med. 180:75–84. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang X, Niu Y, Jian J, Guo Y, Wang Y, Zhu
Y and Liu B: Potential applications of ferroptosis inducers and
regulatory molecules in hematological malignancy therapy. Crit Rev
Oncol Hematol. 193:1042032024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang L, Hobeika CS, Khabibullin D, Yu D,
Filippakis H, Alchoueiry M, Tang Y, Lam HC, Tsvetkov P, Georgiou G,
et al: Hypersensitivity to ferroptosis in chromophobe RCC is
mediated by a glutathione metabolic dependency and cystine import
via solute carrier family 7 member 11. Proc Natl Acad Sci USA.
119:e21228401192022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alborzinia H, Flórez AF, Kreth S, Brückner
LM, Yildiz U, Gartlgruber M, Odoni DI, Poschet G, Garbowicz K, Shao
C, et al: MYCN mediates cysteine addiction and sensitizes
neuroblastoma to ferroptosis. Nat Cancer. 3:471–485. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li W, Liang L, Liu S, Yi H and Zhou Y:
FSP1: A key regulator of ferroptosis. Trends Mol Med. 29:753–764.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Emmanuel N, Li H, Chen J and Zhang Y:
FSP1, a novel KEAP1/NRF2 target gene regulating ferroptosis and
radioresistance in lung cancers. Oncotarget. 13:1136–1139. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He X, Liang SM, Wang HQ, Tao L, Sun FF,
Wang Y, Zhang C, Huang YC, Xu DX and Chen X: Mitoquinone protects
against acetaminophen-induced liver injury in an FSP1-dependent and
GPX4-independent manner. Toxicol Appl Pharmacol. 465:1164522023.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang H, Zhang Z, Ruan S, Yan Q, Chen Y,
Cui J, Wang X, Huang S and Hou B: Regulation of iron metabolism and
ferroptosis in cancer stem cells. Front Oncol. 13:12515612023.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dixon SJ and Pratt DA: Ferroptosis: A
flexible constellation of related biochemical mechanisms. Mol Cell.
83:1030–1042. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo R, Duan J, Pan S, Cheng F, Qiao Y,
Feng Q, Liu D and Liu Z: The road from AKI to CKD: Molecular
mechanisms and therapeutic targets of ferroptosis. Cell Death Dis.
14:4262023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feng H, Schorpp K, Jin J, Yozwiak CE,
Hoffstrom BG, Decker AM, Rajbhandari P, Stokes ME, Bender HG, Csuka
JM, et al: Transferrin receptor is a specific ferroptosis marker.
Cell Rep. 30:3411–3423.e7. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen H, Wang C, Liu Z, He X, Tang W, He L,
Feng Y, Liu D, Yin Y and Li T: Ferroptosis and Its multifaceted
role in cancer: Mechanisms and therapeutic approach. Antioxidants
(Basel). 11:15042022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Q, Sun T, Yu F, Liu W, Gao J, Chen
J, Zheng H, Liu J, Miao C, Guo H, et al: PAFAH2 suppresses
synchronized ferroptosis to ameliorate acute kidney injury. Nat
Chem Biol. Jan 29–2024.(Epub ahead of print).
|
|
26
|
Wang D, Tang L, Zhang Y, Ge G, Jiang X, Mo
Y, Wu P, Deng X, Li L, Zuo S, et al: Regulatory pathways and drugs
associated with ferroptosis in tumors. Cell Death Dis. 13:5442022.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tian X, Li S and Ge G: Apatinib promotes
ferroptosis in colorectal cancer cells by targeting ELOVL6/ACSL4
signaling. Cancer Manag Res. 13:1333–1342. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Zheng L, Shang W, Yang Z, Li T,
Liu F, Shao W, Lv L, Chai L, Qu L, et al: Wnt/beta-catenin
signaling confers ferroptosis resistance by targeting GPX4 in
gastric cancer. Cell Death Differ. 29:2190–2202. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ye Y, Chen A, Li L, Liang Q, Wang S, Dong
Q, Fu M, Lan Z, Li Y, Liu X, et al: Repression of the antiporter
SLC7A11/glutathione/glutathione peroxidase 4 axis drives
ferroptosis of vascular smooth muscle cells to facilitate vascular
calcification. Kidney Int. 102:1259–1275. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Krümmel B, Plötz T, Jörns A, Lenzen S and
Mehmeti I: The central role of glutathione peroxidase 4 in the
regulation of ferroptosis and its implications for pro-inflammatory
cytokine-mediated beta-cell death. Biochim Biophys Acta Mol Basis
Dis. 1867:1661142021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu S, Zhang HL, Li J, Ye ZP, Du T, Li LC,
Guo YQ, Yang D, Li ZL, Cao JH, et al: Tubastatin A potently
inhibits GPX4 activity to potentiate cancer radiotherapy through
boosting ferroptosis. Redox Biol. 62:1026772023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nishida Xavier da Silva T, Friedmann
Angeli JP and Ingold I: GPX4: Old lessons, new features. Biochem
Soc Trans. 50:1205–1213. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen T, Leng J, Tan J, Zhao Y, Xie S, Zhao
S, Yan X, Zhu L, Luo J, Kong L and Yin Y: Discovery of novel potent
covalent glutathione peroxidase 4 inhibitors as highly selective
ferroptosis inducers for the treatment of triple-negative breast
cancer. J Med Chem. 66:10036–10059. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li D, Zhang M and Chao H: Significance of
glutathione peroxidase 4 and intracellular iron level in ovarian
cancer cells-‘utilization’ of ferroptosis mechanism. Inflamm Res.
70:1177–1189. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ursini F and Maiorino M: Lipid
peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic
Biol Med. 152:175–185. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rochette L, Dogon G, Rigal E, Zeller M,
Cottin Y and Vergely C: Lipid peroxidation and iron metabolism: Two
corner stones in the homeostasis control of ferroptosis. Int J Mol
Sci. 24:4492022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Y, Swanda RV, Nie L, Liu X, Wang C,
Lee H, Lei G, Mao C, Koppula P, Cheng W, et al: mTORC1 couples
cyst(e)ine availability with GPX4 protein synthesis and ferroptosis
regulation. Nat Commun. 12:15892021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Koppula P, Zhuang L and Gan B: Cystine
transporter SLC7A11/xCT in cancer: Ferroptosis, nutrient
dependency, and cancer therapy. Protein Cell. 12:599–620. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen M, Shi Z, Sun Y, Ning H, Gu X and
Zhang L: Prospects for anti-tumor mechanism and potential clinical
application based on glutathione peroxidase 4 mediated ferroptosis.
Int J Mol Sci. 24:16072023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jiang Y, Zhao J, Li R, Liu Y, Zhou L, Wang
C, Lv C, Gao L and Cui D: CircLRFN5 inhibits the progression of
glioblastoma via PRRX2/GCH1 mediated ferroptosis. J Exp Clin Cancer
Res. 41:3072022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hu Q, Wei W, Wu D, Huang F, Li M, Li W,
Yin J, Peng Y, Lu Y, Zhao Q and Liu L: Blockade of GCH1/BH4 axis
activates ferritinophagy to mitigate the resistance of colorectal
cancer to erastin-induced ferroptosis. Front Cell Dev Biol.
10:8103272022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kraft VAN, Bezjian CT, Pfeiffer S,
Ringelstetter L, Müller C, Zandkarimi F, Merl-Pham J, Bao X,
Anastasov N, Kössl J, et al: GTP cyclohydrolase
1/tetrahydrobiopterin counteract ferroptosis through lipid
remodeling. ACS Cent Sci. 6:41–53. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Soula M, Weber RA, Zilka O, Alwaseem H, La
K, Yen F, Molina H, Garcia-Bermudez J, Pratt DA and Birsoy K:
Metabolic determinants of cancer cell sensitivity to canonical
ferroptosis inducers. Nat Chem Biol. 16:1351–1360. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lv Y, Wu M, Wang Z and Wang J:
Ferroptosis: From regulation of lipid peroxidation to the treatment
of diseases. Cell Biol Toxicol. 39:827–851. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang S, Kang L, Dai X, Chen J, Chen Z,
Wang M, Jiang H, Wang X, Bu S, Liu X, et al: Manganese induces
tumor cell ferroptosis through type-I IFN dependent inhibition of
mitochondrial dihydroorotate dehydrogenase. Free Radic Biol Med.
193:202–212. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Amos A, Amos A, Wu L and Xia H: The
Warburg effect modulates DHODH role in ferroptosis: A review. Cell
Commun Signal. 21:1002023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee
H, Koppula P, Wu S, Zhuang L, Fang B, et al: DHODH-mediated
ferroptosis defence is a targetable vulnerability in cancer.
Nature. 593:586–590. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang F and Min J: DHODH tangoing with GPX4
on the ferroptotic stage. Signal Transduct Target Ther. 6:2442021.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Desler C, Durhuus JA, Hansen TL, Anugula
S, Zelander NT, Bøggild S and Rasmussen LJ: Partial inhibition of
mitochondrial-linked pyrimidine synthesis increases tumorigenic
potential and lysosome accumulation. Mitochondrion. 64:73–81. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tarangelo A, Rodencal J, Kim JT, Magtanong
L, Long JZ and Dixon SJ: Nucleotide biosynthesis links glutathione
metabolism to ferroptosis sensitivity. Life Sci Alliance.
5:e2021011572022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang C, Zhao Y, Wang L, Guo Z, Ma L, Yang
R, Wu Y, Li X, Niu J, Chu Q, et al: De novo pyrimidine biosynthetic
complexes support cancer cell proliferation and ferroptosis
defence. Nat Cell Biol. 25:836–847. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liu Y, Lu S, Wu LL, Yang L, Yang L and
Wang J: The diversified role of mitochondria in ferroptosis in
cancer. Cell Death Dis. 14:5192023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liang D, Feng Y, Zandkarimi F, Wang H,
Zhang Z, Kim J, Cai Y, Gu W, Stockwell BR and Jiang X: Ferroptosis
surveillance independent of GPX4 and differentially regulated by
sex hormones. Cell. 186:2748–2764.e22. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sun S, Shen J, Jiang J, Wang F and Min J:
Targeting ferroptosis opens new avenues for the development of
novel therapeutics. Signal Transduct Target Ther. 8:3722023.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zeng F, Chen X and Deng G: The
anti-ferroptotic role of FSP1: Current molecular mechanism and
therapeutic approach. Mol Biomed. 3:372022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang Y, Wu X, Ren Z, Li Y, Zou W, Chen J
and Wang H: Overcoming cancer chemotherapy resistance by the
induction of ferroptosis. Drug Resist Updat. 66:1009162023.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen Z, Wang W, Abdul Razak SR, Han T,
Ahmad NH and Li X: Ferroptosis as a potential target for cancer
therapy. Cell Death Dis. 14:4602023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Novo N, Ferreira P and Medina M: The
apoptosis-inducing factor family: Moonlighting proteins in the
crosstalk between mitochondria and nuclei. IUBMB Life. 73:568–581.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zheng J and Conrad M: The metabolic
underpinnings of ferroptosis. Cell Metab. 32:920–937. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Nguyen HP, Yi D, Lin F, Viscarra JA,
Tabuchi C, Ngo K, Shin G, Lee AY, Wang Y and Sul HS: Aifm2, a NADH
oxidase, supports robust glycolysis and is required for cold- and
diet-induced thermogenesis. Mol Cell. 77:600–617.e4. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Mishima E, Ito J, Wu Z, Nakamura T, Wahida
A, Doll S, Tonnus W, Nepachalovich P, Eggenhofer E, Aldrovandi M,
et al: A non-canonical vitamin K cycle is a potent ferroptosis
suppressor. Nature. 608:778–783. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hadian K: Ferroptosis suppressor protein 1
(FSP1) and coenzyme Q10 cooperatively suppress
ferroptosis. Biochemistry. 59:637–638. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Lee J and Roh JL: Unleashing ferroptosis
in human cancers: Targeting ferroptosis suppressor protein 1 for
overcoming therapy resistance. Antioxidants (Basel). 12:12182023.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yuan J, Lv T, Yang J, Wu Z, Yan L, Yang J
and Shi Y: HDLBP-stabilized lncFAL inhibits ferroptosis
vulnerability by diminishing Trim69-dependent FSP1 degradation in
hepatocellular carcinoma. Redox Biol. 58:1025462022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhang S, Gou S, Zhang Q, Yong X, Gan B and
Jia D: FSP1 oxidizes NADPH to suppress ferroptosis. Cell Res.
33:967–970. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lv Y, Liang C, Sun Q, Zhu J, Xu H, Li X,
Li YY, Wang Q, Yuan H, Chu B and Zhu D: Structural insights into
FSP1 catalysis and ferroptosis inhibition. Nat Commun. 14:59332023.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Guo J, Chen L and Ma M: Ginsenoside Rg1
suppresses ferroptosis of renal tubular epithelial cells in
sepsis-induced acute kidney injury via the
FSP1-CoQ10-NAD(P)H pathway. Curr Med Chem. 31:2119–2132.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yang M, Tsui MG, Tsang JKW, Goit RK, Yao
KM, So KF, Lam WC and Lo ACY: Involvement of FSP1-CoQ(10)-NADH and
GSH-GPx-4 pathways in retinal pigment epithelium ferroptosis. Cell
Death Dis. 13:4682022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Santoro MM: The antioxidant role of
non-mitochondrial CoQ10:. Mystery solved! Cell Metab. 31:13–15.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Koppula P, Lei G, Zhang Y, Yan Y, Mao C,
Kondiparthi L, Shi J, Liu X, Horbath A, Das M, et al: A targetable
CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1
inactive lung cancers. Nat Commun. 13:22062022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Shen G, Li C, Cao Q, Megta AK, Li S, Gao
M, Liu H, Shen Y, Chen Y, Yu H, et al: Structural features
determining the vitamin K epoxide reduction activity in the VKOR
family of membrane oxidoreductases. FEBS J. 289:4564–4579. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Mladěnka P, Macáková K, Kujovská Krčmová
L, Javorská L, Mrštná K, Carazo A, Protti M, Remião F and Nováková
L; OEMONOM researchers collaborators, : Vitamin K-sources,
physiological role, kinetics, deficiency, detection, therapeutic
use, and toxicity. Nutr Rev. 80:677–698. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Jin DY, Chen X, Liu Y, Williams CM,
Pedersen LC, Stafford DW and Tie JK: A genome-wide CRISPR-Cas9
knockout screen identifies FSP1 as the warfarin-resistant vitamin K
reductase. Nat Commun. 14:8282023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Mishima E, Wahida A, Seibt T and Conrad M:
Diverse biological functions of vitamin K: From coagulation to
ferroptosis. Nat Metab. 5:924–932. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ward NP and DeNicola GM: Long-sought
mediator of vitamin K recycling discovered. Nature. 608:673–674.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Pfitzner AK, Mercier V, Jiang X, Moser von
Filseck J, Baum B, Šarić A and Roux A: An ESCRT-III polymerization
sequence drives membrane deformation and fission. Cell.
182:1140–1155.e18. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Liu J, Kang R and Tang D:
ESCRT-III-mediated membrane repair in cell death and tumor
resistance. Cancer Gene Ther. 28:1–4. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Dai E, Meng L, Kang R, Wang X and Tang D:
ESCRT-III-dependent membrane repair blocks ferroptosis. Biochem
Biophys Res Commun. 522:415–421. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Shakya A, McKee NW, Dodson M, Chapman E
and Zhang DD: Anti-ferroptotic effects of Nrf2: Beyond the
antioxidant response. Mol Cells. 46:165–175. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Anandhan A, Dodson M, Shakya A, Chen J,
Liu P, Wei Y, Tan H, Wang Q, Jiang Z, Yang K, et al: NRF2 controls
iron homeostasis and ferroptosis through HERC2 and VAMP8. Sci Adv.
9:eade95852023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
He F, Ru X and Wen T: NRF2, a
transcription factor for stress response and beyond. Int J Mol Sci.
21:47772020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Müller F, Lim JKM, Bebber CM, Seidel E,
Tishina S, Dahlhaus A, Stroh J, Beck J, Yapici FI, Nakayama K, et
al: Elevated FSP1 protects KRAS-mutated cells from ferroptosis
during tumor initiation. Cell Death Differ. 30:442–456. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chen L, Cai Q, Yang R, Wang H, Ling H, Li
T, Liu N, Wang Z, Sun J, Tao T, et al: GINS4 suppresses ferroptosis
by antagonizing p53 acetylation with Snail. Proc Natl Acad Sci USA.
120:e22195851202023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zheng X, Wang Q, Zhou Y, Zhang D, Geng Y,
Hu W, Wu C, Shi Y and Jiang J: N-acetyltransferase 10 promotes
colon cancer progression by inhibiting ferroptosis through
N4-acetylation and stabilization of ferroptosis suppressor protein
1 (FSP1) mRNA. Cancer Commun (Lond). 42:1347–1366. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wang N, Ma T and Yu B: Targeting
epigenetic regulators to overcome drug resistance in cancers.
Signal Transduct Target Ther. 8:692023. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wu J, Zhu S, Wang P, Wang J, Huang J, Wang
T, Guo L, Liang D, Meng Q and Pan H: Regulators of epigenetic
change in ferroptosis-associated cancer (review). Oncol Rep.
48:2152022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hao M, Jiang Y, Zhang Y, Yang X and Han J:
Ferroptosis regulation by methylation in cancer. Biochim Biophys
Acta Rev Cancer. 1878:1889722023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Wang Y, Hu J, Wu S, Fleishman JS, Li Y, Xu
Y, Zou W, Wang J, Feng Y, Chen J and Wang H: Targeting epigenetic
and posttranslational modifications regulating ferroptosis for the
treatment of diseases. Signal Transduct Target Ther. 8:4492023.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wu X, Xu M, Geng M, Chen S, Little PJ, Xu
S and Weng J: Targeting protein modifications in metabolic
diseases: Molecular mechanisms and targeted therapies. Signal
Transduct Target Ther. 8:2202023. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Lee J and Roh JL: Epigenetic modulation of
ferroptosis in cancer: Identifying epigenetic targets for novel
anticancer therapy. Cell Oncol (Dordr). 46:1605–1623. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Widagdo J, Anggono V and Wong JJL: The
multifaceted effects of YTHDC1-mediated nuclear m6A
recognition. Trends Genet. 38:325–332. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Yuan S, Xi S, Weng H, Guo MM, Zhang JH, Yu
ZP, Zhang H, Yu Z, Xing Z, Liu MY, et al: YTHDC1 as a tumor
progression suppressor through modulating FSP1-dependent
ferroptosis suppression in lung cancer. Cell Death Differ.
30:2477–2490. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Brewer G: FSP1 in cancer: Not just a
phase. Nat Rev Cancer. 23:5782023. View Article : Google Scholar
|
|
94
|
Zhang Q, Li N, Deng L, Jiang X, Zhang Y,
Lee LTO and Zhang H: ACSL1-induced ferroptosis and platinum
resistance in ovarian cancer by increasing FSP1 N-myristylation and
stability. Cell Death Discov. 9:832023. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Liu MR, Shi C, Song QY, Kang MJ, Jiang X,
Liu H and Pei DS: Sorafenib induces ferroptosis by promoting
TRIM54-mediated FSP1 ubiquitination and degradation in
hepatocellular carcinoma. Hepatol Commun. 7:e02462023. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Gotorbe C, Durivault J, Meira W, Cassim S,
Ždralević M, Pouysségur J and Vučetić M: Metabolic rewiring toward
oxidative phosphorylation disrupts intrinsic resistance to
ferroptosis of the colon adenocarcinoma cells. Antioxidants
(Basel). 11:24122022. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Pontel LB, Bueno-Costa A, Morellato AE,
Carvalho Santos J, Roué G and Esteller M: Acute lymphoblastic
leukemia necessitates GSH-dependent ferroptosis defenses to
overcome FSP1-epigenetic silencing. Redox Biol. 55:1024082022.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Yoshioka H, Kawamura T, Muroi M, Kondoh Y,
Honda K, Kawatani M, Aono H, Waldmann H, Watanabe N and Osada H:
Identification of a Small molecule that enhances ferroptosis via
inhibition of ferroptosis suppressor protein 1 (FSP1). ACS Chem
Biol. 17:483–491. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Cheu JW, Lee D, Li Q, Goh CC, Bao MH, Yuen
VW, Zhang MS, Yang C, Chan CY, Tse AP, et al: Ferroptosis
suppressor protein 1 inhibition promotes tumor ferroptosis and
anti-tumor immune responses in liver cancer. Cell Mol Gastroenterol
Hepatol. 16:133–159. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Xavier da Silva TN, Schulte C, Alves AN,
Maric HM and Friedmann Angeli JP: Molecular characterization of
AIFM2/FSP1 inhibition by iFSP1-like molecules. Cell Death Dis.
14:2812023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Hendricks JM, Doubravsky CE, Wehri E, Li
Z, Roberts MA, Deol KK, Lange M, Lasheras-Otero I, Momper JD, Dixon
SJ, et al: Identification of structurally diverse FSP1 inhibitors
that sensitize cancer cells to ferroptosis. Cell Chem Biol.
30:1090–1103.e7. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Xavier da Silva TN and Friedmann Angeli
JP: Sabotaging the breaks: FSEN1 expands the toolbox of FSP1
inhibitors. Cell Chem Biol. 30:1006–1008. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Nakamura T, Hipp C, Santos Dias Mourão A,
Borggräfe J, Aldrovandi M, Henkelmann B, Wanninger J, Mishima E,
Lytton E, Emler D, et al: Phase separation of FSP1 promotes
ferroptosis. Nature. 619:371–377. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Nakamura T, Mishima E, Yamada N, Mourão
ASD, Trümbach D, Doll S, Wanninger J, Lytton E, Sennhenn P, Nishida
Xavier da Silva T, et al: Integrated chemical and genetic screens
unveil FSP1 mechanisms of ferroptosis regulation. Nat Struct Mol
Biol. 30:1806–1815. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Tang W, Chen Z, Zhang W, Cheng Y, Zhang B,
Wu F, Wang Q, Wang S, Rong D, Reiter FP, et al: The mechanisms of
sorafenib resistance in hepatocellular carcinoma: Theoretical basis
and therapeutic aspects. Signal Transduct Target Ther. 5:872020.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Lai YL, Wang KH, Hsieh HP and Yen WC:
Novel FLT3/AURK multikinase inhibitor is efficacious against
sorafenib-refractory and sorafenib-resistant hepatocellular
carcinoma. J Biomed Sci. 29:52022. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Mishima E, Nakamura T, Zheng J, Zhang W,
Mourão ASD, Sennhenn P and Conrad M: DHODH inhibitors sensitize to
ferroptosis by FSP1 inhibition. Nature. 619:E9–E18. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zhang L, Zhang J, Wang J, Ren C, Tang P,
Ouyang L and Wang Y: Recent advances of human dihydroorotate
dehydrogenase inhibitors for cancer therapy: Current development
and future perspectives. Eur J Med Chem. 232:1141762022. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Zhou J, Zhang L, Yan J, Hou A, Sui W and
Sun M: Curcumin induces ferroptosis in A549 CD133+ cells
through the GSH-GPX4 and FSP1-CoQ10-NAPH pathways. Discov Med.
35:251–263. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Miyazaki K, Xu C, Shimada M and Goel A:
Curcumin and andrographis exhibit anti-tumor effects in colorectal
cancer via activation of ferroptosis and dual suppression of
glutathione peroxidase-4 and ferroptosis suppressor protein-1.
Pharmaceuticals (Basel). 16:3832023. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Yang J, Jia Z, Zhang J, Pan X, Wei Y, Ma
S, Yang N, Liu Z and Shen Q: Metabolic intervention nanoparticles
for triple-negative breast cancer therapy via overcoming
FSP1-mediated ferroptosis resistance. Adv Healthc Mater.
11:e21027992022. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Li K, Lin C, Li M, Xu K, He Y, Mao Y, Lu
L, Geng W, Li X, Luo Z and Cai K: Multienzyme-like reactivity
cooperatively impairs glutathione peroxidase 4 and ferroptosis
suppressor protein 1 pathways in triple-negative breast cancer for
sensitized ferroptosis therapy. ACS Nano. 16:2381–2398. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Liu C, Xing J, Akakuru OU, Luo L, Sun S,
Zou R, Yu Z, Fang Q and Wu A: Nanozymes-engineered metal-organic
frameworks for catalytic cascades-enhanced synergistic cancer
therapy. Nano Lett. 19:5674–5682. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Ding Y, Xu H, Xu C, Tong Z, Zhang S, Bai
Y, Chen Y, Xu Q, Zhou L, Ding H, et al: A nanomedicine fabricated
from gold nanoparticles-decorated metal-organic framework for
cascade chemo/chemodynamic cancer therapy. Adv Sci (Weinh).
7:20010602020. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Zhou Y, Chen K, Lin WK, Liu J, Kang W,
Zhang Y, Yang R, Jin L, Cheng Y, Xu A and Wang W: Photo-enhanced
synergistic induction of ferroptosis for anti-cancer immunotherapy.
Adv Healthc Mater. 12:e23009942023. View Article : Google Scholar : PubMed/NCBI
|
